CTMX CYTOMX THERAPEUTICS INC Investments/Divestments 8-K Filing 2023 - Collaboration Agreement CytomX Therapeutics entered into a Collaboration and License Agreement with Moderna to develop mRNA-based therapies for oncology and non-oncology conditions, with an upfront cash payment of $35 million and potential milestone payments of up to $1.2 billion.Get access to all SEC 8-K filings of the CYTOMX THERAPEUTICS INC